Publicaciones en colaboración con investigadores/as de University Hospital of Lausanne (15)

2024

  1. Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R

    ESMO Open, Vol. 9, Núm. 6

2023

  1. Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey

    ESMO Open, Vol. 8, Núm. 2

  2. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

    Journal of Thoracic Oncology, Vol. 18, Núm. 2, pp. 181-193

2022

  1. A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry

    Journal of Thoracic Oncology, Vol. 17, Núm. 5, pp. 661-674

  2. Erratum: Perception and Improvisation of Gender Climate in Oncology and Role of International and National Societies (Indian Journal of Medical and Paediatric Oncology 43:1 (4-7) DOI: 10.1055/s-0042-1742656)

    Indian Journal of Medical and Paediatric Oncology

  3. Perception and Improvisation of Gender Climate in Oncology and Role of International and National Societies

    Indian Journal of Medical and Paediatric Oncology, Vol. 43, Núm. 1, pp. 4-7

2021

  1. Female leadership in oncology—has progress stalled? Data from the ESMO W4O authorship and monitoring studies

    ESMO Open, Vol. 6, Núm. 6

  2. Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey

    ESMO Open, Vol. 6, Núm. 3, pp. 1-7

2020

  1. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

    The Lancet Oncology, Vol. 21, Núm. 7, pp. 914-922

  2. European Society for Medical Oncology (ESMO) 2018 Congress Twitter analysis: From ethics to results through the understanding of communication and interaction flows

    ESMO Open, Vol. 5, Núm. 1

  3. Gender gap: Surveying the world for tomorrow

    ESMO Open

  4. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

    Annals of Oncology, Vol. 31, Núm. 10, pp. 1320-1335

2019

  1. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the committee for medicinal products for human use (chmp)

    Annals of Oncology

  2. Trastuzumab emtansine (T-DM1) in patients with previously treated HER2-overexpressing metastatic non–small cell lung cancer: Efficacy, safety, and biomarkers

    Clinical Cancer Research, Vol. 25, Núm. 1, pp. 64-72

2017

  1. The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC

    Journal of Thoracic Oncology, Vol. 12, Núm. 2, pp. 194-207